신경병증성 통증 시장 : 규모, 점유율, 성장, 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of neuropathic pain Market

The global neuropathic pain market was valued at USD 8.26 billion in 2025 and is projected to grow from USD 8.83 billion in 2026 to USD 16.78 billion by 2034, registering a CAGR of 8.35% during the forecast period. The market is witnessing significant growth due to the increasing prevalence of diabetes, cancer, shingles, chemotherapy-induced nerve damage, and other neurological disorders that result in chronic nerve pain. Neuropathic pain therapeutics, including anticonvulsants, antidepressants, opioids, and topical medications, remain the primary treatment options. North America dominated the global market with a 50.66% market share in 2025, supported by strong pharmaceutical presence, high disease awareness, and continuous product innovation.

Market Trends

A key trend driving the neuropathic pain market is the growing investment in research and development of novel pain management therapies. Pharmaceutical and biotechnology companies are actively conducting clinical trials to introduce safer and more effective treatments with fewer side effects. The industry is also witnessing increasing interest in non-opioid therapies, targeted drug delivery systems, and innovative neurological treatments. Several companies are advancing late-stage clinical trials to improve therapeutic outcomes for diabetic neuropathy, trigeminal neuralgia, and chemotherapy-induced neuropathic pain.

Market Drivers

The rising burden of chronic diseases is one of the primary growth drivers of the neuropathic pain market. Diabetes, cancer, multiple sclerosis, kidney diseases, and shingles significantly increase the risk of nerve damage and chronic pain. The growing global diabetic population and increasing cancer incidence have resulted in a larger patient pool requiring long-term neuropathic pain management.

Additionally, increasing product launches and ongoing clinical research are accelerating market growth. Pharmaceutical companies continue to introduce advanced therapeutics to improve pain control and patient quality of life. Growing healthcare awareness and improved diagnosis of neuropathic disorders are further supporting market expansion across developed and emerging economies.

Market Restraints

Despite favorable market growth, the widespread use of neuropathic pain medications is limited by the side effects associated with existing therapies. Drugs such as pregabalin and gabapentin may cause dizziness, drowsiness, dry mouth, blurred vision, edema, and fatigue, affecting patient compliance. Due to these adverse effects, many patients prefer alternative pain management approaches, including implantable medical devices, nerve stimulation therapies, and surgical interventions, which may restrain pharmaceutical market growth.

Market Segmentation

Based on drug class, the anticonvulsants segment is expected to dominate the market with a 28.92% share in 2026. The strong demand for drugs such as Lyrica, Neurontin, Gralise, Horizant, and OXTELLAR XR for diabetic neuropathy management continues to support segment growth. Meanwhile, the others segment is anticipated to register the fastest growth due to ongoing development of novel therapeutics.

By application, the chemotherapy-induced neuropathy segment is projected to account for 39.48% of the global market in 2026, driven by the increasing number of cancer patients receiving chemotherapy. The diabetic neuropathy segment is also expected to witness robust growth due to the rising prevalence of diabetes worldwide and increasing research focused on advanced treatment options.

Based on route of administration, the oral segment is expected to hold 77.15% of the market in 2026 owing to the wide availability and convenience of oral medications. The parenteral segment is anticipated to experience healthy growth as companies continue developing injectable therapies for severe neuropathic pain conditions.

By distribution channel, the retail pharmacy segment is projected to capture 68.61% of the global market in 2026, supported by easy access to prescription and over-the-counter medications. Online pharmacies are expected to witness the fastest growth due to increasing digital healthcare adoption and home delivery services.

Regional Insights

North America accounted for USD 4.18 billion in 2025 and is projected to reach USD 4.51 billion in 2026. The region dominates the global market due to the strong presence of leading pharmaceutical companies, growing prevalence of diabetes and cancer, and high awareness regarding neuropathic pain treatment.

Europe generated USD 2.28 billion in 2025 and is expected to reach USD 2.42 billion in 2026. Rising cases of diabetes and cancer, combined with increasing pharmaceutical research activities, continue to drive market expansion across the region.

Asia Pacific reached USD 1.00 billion in 2025 and is projected to grow to USD 1.07 billion in 2026. Growth is supported by expanding clinical research, rising healthcare expenditure, increasing diabetic population, and ongoing development of innovative therapeutics in countries such as China, Japan, and India.

Latin America generated USD 0.46 billion in 2025 and is estimated to reach USD 0.49 billion in 2026, while the Middle East & Africa market stood at USD 0.33 billion in 2025 and is projected to reach USD 0.34 billion in 2026, driven by improving healthcare infrastructure and increasing awareness of chronic pain management.

Key Market Players

Major companies operating in the global neuropathic pain market include Almatica, Azurity Pharmaceuticals, Pfizer Inc., Viatris Inc., Supernus Pharmaceuticals, Novartis AG, Accord Healthcare, Focus Health Group, Amneal Pharmaceuticals LLC, Abbott, and Teva Pharmaceutical Industries Ltd. These companies continue investing in acquisitions, partnerships, product launches, and clinical research to strengthen their market presence.

Key Industry Developments

Recent developments highlight the industry's strong focus on innovation. In May 2024, Lexicon Pharmaceuticals partnered with Medidata for its Phase 2b clinical study of LX9211 for diabetic neuropathy pain. In April 2024, Vertex Pharmaceuticals announced advancements in Suzetrigine, a selective NaV1.8 pain inhibitor for diabetic neuropathy. In September 2023, Azurity Pharmaceuticals acquired Slayback Pharma to strengthen research and development capabilities. Earlier, Novo Nordisk expanded its chronic disease portfolio through the acquisition of BIOCORP, while Almatica Pharma continued expanding its neuropathic pain product portfolio through new antidepressant launches.

Conclusion

The global neuropathic pain market is expected to experience strong growth through 2034, supported by the rising prevalence of diabetes, cancer, neurological disorders, and an aging population. Continuous investment in innovative drug development, expanding clinical trials, and increasing healthcare awareness are expected to create significant growth opportunities. Although medication-related side effects remain a key challenge, the development of safer, targeted, and non-opioid therapies is likely to transform neuropathic pain management and drive long-term market expansion.

Segmentation By Drug Class

• Anticonvulsants
• Tricyclic Antidepressants (TCA)
• Opioids
• Capsaicinoids
• Others

By Application

• Diabetic Neuropathy
• Chemotherapy Induced Neuropathy
• Sciatic Neuropathy
• Others

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region

• North America (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and By Country)
  • U.S.
  • Canada
• Europe (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and By Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and BY Country/Sub-region)
  • Japan
  • China
  • Australia
  • India
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and By Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and By Country/Sub-region)
  • South Africa
  • GCC
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Neuropathic pain - by Key Countries/Sub-regions, 2025
• 4.2. Pipeline Analysis - by Key Players
• 4.3. New Product launches - by Key Players
• 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.5. Impact of COVID-19 on the Market

5. Global Neuropathic Pain Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. Anticonvulsants
  • 5.1.2. Tricyclic Antidepressant (TCA)
  • 5.1.3. Opioids
  • 5.1.4. Capsaicinoids
  • 5.1.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Diabetic Neuropathy
  • 5.2.2. Chemotherapy Induced Neuropathy
  • 5.2.3. Sciatic Neuropathy
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Oral
  • 5.3.2. Parenteral
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacy
  • 5.4.2. Retail Pharmacy
  • 5.4.3. Online Pharmacy
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Neuropathic Pain Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. Anticonvulsants
  • 6.1.2. Tricyclic Antidepressant (TCA)
  • 6.1.3. Opioids
  • 6.1.4. Capsaicinoids
  • 6.1.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Diabetic Neuropathy
  • 6.2.2. Chemotherapy Induced Neuropathy
  • 6.2.3. Sciatic Neuropathy
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.3.1. Oral
  • 6.3.2. Parenteral
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital Pharmacy
  • 6.4.2. Retail Pharmacy
  • 6.4.3. Online Pharmacy
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Neuropathic Pain Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. Anticonvulsants
  • 7.1.2. Tricyclic Antidepressant (TCA)
  • 7.1.3. Opioids
  • 7.1.4. Capsaicinoids
  • 7.1.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Diabetic Neuropathy
  • 7.2.2. Chemotherapy Induced Neuropathy
  • 7.2.3. Sciatic Neuropathy
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.3.1. Oral
  • 7.3.2. Parenteral
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital Pharmacy
  • 7.4.2. Retail Pharmacy
  • 7.4.3. Online Pharmacy
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Neuropathic Pain Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. Anticonvulsants
  • 8.1.2. Tricyclic Antidepressant (TCA)
  • 8.1.3. Opioids
  • 8.1.4. Capsaicinoids
  • 8.1.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Diabetic Neuropathy
  • 8.2.2. Chemotherapy Induced Neuropathy
  • 8.2.3. Sciatic Neuropathy
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.3.1. Oral
  • 8.3.2. Parenteral
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital Pharmacy
  • 8.4.2. Retail Pharmacy
  • 8.4.3. Online Pharmacy
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. Japan
  • 8.5.2. Australia
  • 8.5.3. China
  • 8.5.4. India
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Neuropathic Pain Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. Anticonvulsants
  • 9.1.2. Tricyclic Antidepressant (TCA)
  • 9.1.3. Opioids
  • 9.1.4. Capsaicinoids
  • 9.1.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Diabetic Neuropathy
  • 9.2.2. Chemotherapy Induced Neuropathy
  • 9.2.3. Sciatic Neuropathy
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.3.1. Oral
  • 9.3.2. Parenteral
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital Pharmacy
  • 9.4.2. Retail Pharmacy
  • 9.4.3. Online Pharmacy
• 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Neuropathic Pain Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. Anticonvulsants
  • 10.1.2. Tricyclic Antidepressant (TCA)
  • 10.1.3. Opioids
  • 10.1.4. Capsaicinoids
  • 10.1.5. Others
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Diabetic Neuropathy
  • 10.2.2. Chemotherapy Induced Neuropathy
  • 10.2.3. Sciatic Neuropathy
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.3.1. Oral
  • 10.3.2. Parenteral
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital Pharmacy
  • 10.4.2. Retail Pharmacy
  • 10.4.3. Online Pharmacy
• 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.5.1. South Africa
  • 10.5.2. GCC
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Almatica
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Azurity Pharmaceuticals, Inc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Pfizer Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Viatris Inc.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Supernus Pharmaceuticals, Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Novartis AG
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Accord Healthcare
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Focus Health Group
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Amneal Pharmaceuticals LLC
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Abbott
    • 11.2.10.1. Overview
    • 11.2.10.2. Products
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)
  • 11.2.11. Teva Pharmaceutical Industries Ltd.
    • 11.2.11.1. Overview
    • 11.2.11.2. Products
    • 11.2.11.3. SWOT Analysis
    • 11.2.11.4. Recent Developments
    • 11.2.11.5. Strategies
    • 11.2.11.6. Financials (Based on Availability)